FYI from the NHLBI Index
May 2004: Vol. 5, Issue 1
Please email your suggestions for future FYI from the NHLBI articles to
Rare Lung Diseases Consortium Meets
The first annual meeting of the Rare
Lung Diseases Consortium (RLDC) was held in Cincinnati, Ohio, March 26-28,
2004. The National Center for Research Resources/NIH Rare Lung Diseases Consortium
is a Cincinnati-based international network of clinical centers that are focused
on clinical research in rare pulmonary diseases, including lymphangioleiomyomatosis
(LAM), alpha one antitrypsin deficiency (AATD), pulmonary alveolar proteinosis
(PAP), and pediatric interstitial lung disease (pILD).
The meeting was modeled after prior LAM conferences, and included nearly 400
clinicians, scientists, patients, and NIH staff. Like "LAMposium,"
a unique and powerful aspect of the RLDC conference was the inspiration and
synergy that resulted from the interactions among the scientific participants
and the patients. Deliberate efforts were made to attract investigators from
diverse disciplines, to introduce novel thinking, and to set new research directions.
Dr. Betsy Nabel's address to the patients on "The Value of Patient Advocacy
in NHLBI-sponsored Translational Research" was a highlight of the meeting.
The pathogenesis of autoimmune lung disease was one theme that emerged as a
focus for next year's Cincinnati RLDC meeting scheduled for April 8-10, 2005.
The NHLBI and the Office of Rare Diseases supported this conference through
the R13 mechanism with awards to Drs. Frank McCormack for LAM, Bruce Trapnell
for PAP, and Robin Deterding for pILD.
Article contributed by:
Drs. Frank McCormack and Bruce Trapnell,
University of Cincinnati.
Educational Series to Inform Patients about the Fourth Most
Common Cause of Death in the United States
Educating the patient community about a major national health problem that
accounts for 8 million office visits, costs over $32 billion dollars in medical
expenditures, and is the fourth leading cause of death in the United States
and advising this same community on the most efficacious treatments and prevention
strategies is the objective of a new series of all-day seminars organized by
the Alpha-1 Foundation:
The 2004 COPD and Alpha-1 Education Days Series. Other co-sponsors of the series
include the Alpha-1
Association, the National Emphysema/COPD Association, and the NHLBI COPD
Clinical Research Network (CRN).
Chronic obstructive pulmonary disease (COPD) is a major public health problem
that affects more than 16 million Americans. COPD is an umbrella term used to
describe airflow obstruction associated with emphysema and chronic bronchitis.
Alpha-1 antitrypsin deficiency (Alpha-1) is one of the most common hereditary
disorders in the world and can result in life-threatening lung disease in adults
and liver disease in children and adults. An estimated 100,000 Americans have
the deficiency, yet less than 10 percent have been diagnosed. As many as 25
million people in the United States could carry a single deficient gene that
causes Alpha1 and may pass the gene on to their children.
So what's the connection between COPD and Alpha-1? "Alpha-1 is a strong
risk factor for COPD," states David Mannino, M.D., Medical Epidemiologist
at the National Center for Environmental Health, Centers for Disease Control
and Prevention. "I firmly believe a high percentage of COPD is related
to genetics, unfortunately we only know the specific genetic cause of a small
percentage." Approximately three percent of people with COPD may have Alpha-1.
"When I learned the Alpha-1 Education Days series was going to be expanded
to include COPD, I was pleased with the aims and thought it was important that
the NHLBI COPD CRN was offered the opportunity to participate," stated
James Kiley, Ph.D., Director, Division of Lung Diseases, NHLBI. The 2004 COPD
and Alpha-1 Education Days Series incorporates the successful Alpha-1 Education
Days and includes outreach to the COPD community offering educational programming
to individuals affected by Alpha-1 and COPD throughout the country. This community-based
effort increases general awareness by including a broader segment of the affected
population. "There is a tremendous need for greater public awareness about
COPD. In recognition of this need, the NHLBI is developing a COPD education
program to reach patients and clinicians," Dr. Kiley added.
In 1998, a task force led by representatives from the American Thoracic Society
(ATS) and the European Respiratory Society (ERS) began a systematic review of
the diagnosis and management of individuals with Alpha-1. The result of their
5-year study established new guidelines for physicians. Among its most significant
recommendations is diagnostic genetic testing for Alpha-1 for all adults with
emphysema, COPD, irreversible asthma, or unexplained liver disease.
"The guidelines establish a new standard for the detection and treatment
of Alpha-1 because this genetic disorder is often going undiagnosed or misdiagnosed,"
said John W. Walsh, President and CEO, Alpha-1 Foundation. The expanded education
series has come about, in large part, by the announcement of the ATS/ERS consensus
Article contributed by:
Ms. Silvana Piñeiro, Alpha-1
The NHLBI is currently planning a workshop to formulate strategies
for a COPD education program. It will be held in the fall 2004 and representatives
from COPD-related PIOs will be invited.
Please send us your feedback, comments, and questions by using the appropriate link on the page, Contact the NHLBI.
Note to users of screen readers and other assistive technologies: please report your problems here.
PDF Version | Contents | Feature
Articles | In the News | Events and Meetings | Research and Resources
All Issues | FYI Index | NHLBI Express